ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market

<div><p class="dateline">FREMONT, CA - (<a href="https://www.newmediawire.com">NewMediaWire</a>) - January 2, 2025 -<a href="http://abvcpharma.com/"></a>&nbsp;<a href="http://abvcpharma.com/">ABVC BioPharma, Inc.</a> (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in ophthalmology, neurology, and oncology/hematology, is announcing the approval of its patent application by Taiwan&rsquo;s Intellectual Property Office (TIPO). The patent, titled <b>"Polygala Extract for Treating Attention Deficit Hyperactivity Disorder (ADHD)"</b> (Application No. 110106546), marks a significant milestone in ABVC&rsquo;s global intellectual property portfolio.</p> <p>This patent adds to ABVC&rsquo;s prior successes, including similar patents granted by the United States Patent and Trademark Office (US Patent No. 17/120,965) in 2021 and the Australian Patent Office (Patent No. 2021403197) in 2024. These approvals collectively reinforce ABVC&rsquo;s strength in developing natural, botanical-based therapies for ADHD.</p> <p>The patented treatment, utilizing Polygala tenuifolia extract, represents a novel approach to addressing the core symptoms of ADHD through its Norepinephrine Transporter (NET) inhibition mechanism. This innovative solution holds promise for patients inadequately managed by existing therapies.</p> <p><b>&ldquo;Strengthening Our Global Position in ADHD Innovation&rdquo;<br /></b>&ldquo;The approval of this patent in Taiwan is a testament to our commitment to advancing ADHD care,&rdquo; <a href="https://abvcpharma.com/?page_id=16723">said Dr. Uttam Patil, ABVC Chief Executive Officer</a>. &ldquo;With patents now granted in three key jurisdictions, we are strategically positioned to expand the global reach of this groundbreaking therapy, in an effort to improve outcomes for patients worldwide.&rdquo;</p> <p><b>Market Potential and Next Steps</b><br />ABVC is actively advancing its ADHD therapy, which is encapsulated in its proprietary drug asset ABV-1505. The treatment has already completed Phase IIa clinical trials, with Phase IIb results expected soon. As per Polaris market research, the global ADHD treatment market is projected to grow from $16.13 billion in 2022 to $32.14 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.1%.<a href="#_ftn1">[1]</a></p> <p>The Company plans to leverage this robust IP foundation to pursue further clinical studies, regulatory clearances, and strategic partnerships globally.</p> <p><b>About ABVC BioPharma &amp; Its Industry<br /></b>ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus&reg;) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus&reg;, the Company intends to conduct global clinical trials through Phase III.</p> <p><b>Forward-Looking Statements<br /></b>This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at&nbsp;<a aria-invalid="true" target="_blank" href="https://www.globenewswire.com/Tracker?data=azKw4VdX46rxhowWBeLVmi0HCLVvSDA2aG7Jmihhj2dlJaErJdLOGb8_6MMKHrmg__chYY4D2TFruxBXxlnbEA==" rel="noopener" style="background-color: #ffffff;">http://www.sec.gov</a>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.</p> <p>This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.</p> <p>Contact:<br />Uttam Patil<br />Email: <a href="mailto:uttam@ambrivis.com">uttam@ambrivis.com</a></p> <p><a href="#_ftnref1">[1]</a> https://www.prnewswire.com/news-releases/global-attention-deficit-hyperactivity-disorder-adhd-market-size-projected-to-reach-usd-32-14-billion-by-2032--with-cagr-of-7-1-study-by-polaris-market-research-301729196.html#:~:text=According%20to%20the%20research%20report</p> <p>&nbsp;</p><p class="nmw_link">View the original release on <a href="https://www.newmediawire.com/nmw_release/?rid=6776864dda846f630f7f4ce8/abvc-biopharma-secures-an-additional-patent-for-adhd-treatment-in-addition-to-the-granted-u-s-and-australian-patents-moving-forward-to-the-global-patent-map-of-32-14-billion-potential-market">www.newmediawire.com</a></p></div>